Nervonik — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Nervonik is a private, pre-revenue medical device company founded in 2019 and based in San Diego, CA. It is developing a novel, patented PNS platform designed to overcome the technical challenges of delivering neuromodulation in areas of high motion, with the goal of improving lead placement, programming, energy efficiency, and long-term efficacy. The company has successfully completed a first-in-human clinical trial, marking a key translational milestone for its technology. Nervonik is led by a seasoned team with extensive experience in neuromodulation, medical device engineering, and commercialization.

Chronic Pain

Technology Platform

Proprietary, patented trifecta technology platform for peripheral nerve stimulation (PNS) designed for high-motion anatomical areas. It integrates biosensing capabilities for objective feedback to enable smarter lead placement, adaptive programming, improved energy efficiency, and enhanced long-term therapy stability.

Opportunities

The multibillion-dollar chronic pain market presents a massive opportunity, with peripheral nerve stimulation (PNS) as a rapidly growing segment.

Nervonik's motion-optimized technology addresses a clear limitation of existing devices, potentially expanding the treatable patient population to active individuals and high-motion anatomical areas.

Success could position the company as a leader in next-generation neuromodulation or an attractive acquisition target for larger medtech firms.

Risk Factors

Key risks include the uncertainty of regulatory approval (FDA PMA pathway) and securing favorable reimbursement.

The company faces significant competition from well-established neuromodulation giants like Medtronic, Abbott, and Boston Scientific.

Technical and clinical risks remain, as the technology must still prove superior efficacy and long-term reliability in larger pivotal trials.

Competitive Landscape

Nervonik competes in the established neuromodulation market dominated by large players like Medtronic, Abbott, Boston Scientific, and Nevro, who offer PNS systems. Its primary competitive advantage is a device specifically engineered for high-motion stability and integrated biosensing, a niche not directly addressed by current market offerings. Success depends on clearly demonstrating this clinical differentiation to overcome incumbents' strong sales channels and physician relationships.

More companies in Neuroscience & CNS →More companies in United States →